People: Aegerion Pharmaceuticals Inc (AEGR.O)
14 Mar 2014
Ms. Anne M. VanLent is Independent Director of Aegerion Pharmaceuticals, Inc., since April 2013. Ms. VanLent is President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. Ms. VanLent had been Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a publicly traded pharmaceutical company that develops and markets prescription dermatology products, from May 2002 through April 2008. From July 1997 to October 2001, she was the Executive Vice President — Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. From 1985 to 1993, she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a publicly-traded biopharmaceutical company. Ms. VanLent currently serves as a director and chair of the audit committee for Tranzyme Pharma, Inc., a NASDAQ-listed company, and as a director of Integra Life Sciences, where she served as chair of the audit committee from 2005 to 2012. During the past five years, Ms. VanLent also served as a director of Penwest Pharmaceuticals Co., until its sale to Endo Pharmaceuticals in the fall of 2010. Ms. VanLent received a B.A. degree in Physics from Mount Holyoke College.
|Total Annual Compensation,||Long-Term Incentive Plans,||All Other,||Fiscal Year Total,|